摘要
ADP核糖聚合酶(PARP)抑制剂是目前已知对于上皮性卵巢癌(EOC)治疗效果较好的药物。高级别浆液性癌是上皮性卵巢癌中最常见的组织学亚型,由于其同源重组缺乏率(HR)较高,PARP抑制剂对其效果尤为明显。PARP抑制剂通过破坏DNA修复,促进肿瘤细胞的死亡。已有研究表明,对于伴有BRCA1/2突变或铂敏感性的复发性上皮性卵巢癌妇女,PARP抑制剂的效果十分显著。目前已有3种PARP抑制剂(Olaparib、Niraparib和Rucaparib)现在被批准用于对铂敏感和铂敏感复发患者的维持治疗。此外,PARP抑制剂也被批准用于有3种或3种以上的既往治疗的伴有BRCA1/2突变的复发性EOC患者的积极治疗。本文主要对EOC中PARP抑制剂的研究现状进行综述。
ADP ribose polymerase(PARP)inhibitors are currently the best known agents for the treatment of epithelial ovarian cancer(EOC).High-grade serous carcinoma is the most common histological subtype of epithelial ovarian cancer.Because of its high homologous recombination rate(HR),PARP inhibitors are particularly effective.PARP inhibitors promote tumor cell death by disrupting DNA repair.Studies have shown that the effect of PARP inhibitors is significant for women with recurrent epithelial ovarian cancer with BRCA1/2 mutation or platinum sensitivity.Three PARP inhibitors(Olaparib,Niraparib,and Rucaparib)are currently approved for maintenance therapy in patients with platinum-sensitive and platinum-sensitive relapses.In addition,PARP inhibitors have also been approved for active treatment of patients with recurrent EOC with BRCA1/2 mutations with 3 or more prior treatments.This paper reviews the research status of PARP inhibitors in EOC.
作者
黄馨禾
董丹丹
刘倩
HUANG Xin-he;DONG Dan-dan;LIU Qian(Department of Obstetrics and Gynecology,the Second Affiliated Hospital of Harbin Medical University,Harbin 165000,Heilongjiang,China)
出处
《医学信息》
2019年第21期26-29,共4页
Journal of Medical Information
关键词
卵巢癌
ADP核糖聚合酶
乳腺癌相关抗原
同源重组
Ovarian cancer
ADP ribose polymerase
Breast cancer-associated antigen
Homologous recombination
